- Home
- SAVA vs ATRA Comparison
SAVA vs ATRA Comparison
Compare SAVA & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- ATRA
- Stock Information
- Founded
- SAVA 1998
- ATRA 2012
- Country
- SAVA United States
- ATRA United States
- Employees
- SAVA N/A
- ATRA N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SAVA Health Care
- ATRA Health Care
- Exchange
- SAVA Nasdaq
- ATRA Nasdaq
- Market Cap
- SAVA 102.4M
- ATRA 97.0M
- IPO Year
- SAVA N/A
- ATRA 2014
- Fundamental
- Price
- SAVA $3.63
- ATRA $14.41
- Analyst Decision
- SAVA Hold
- ATRA Strong Buy
- Analyst Count
- SAVA 1
- ATRA 3
- Target Price
- SAVA $2.00
- ATRA $21.00
- AVG Volume (30 Days)
- SAVA 4.9M
- ATRA 52.1K
- Earning Date
- SAVA 11-06-2025
- ATRA 11-11-2025
- Dividend Yield
- SAVA N/A
- ATRA N/A
- EPS Growth
- SAVA N/A
- ATRA N/A
- EPS
- SAVA N/A
- ATRA 0.56
- Revenue
- SAVA N/A
- ATRA $188,667,000.00
- Revenue This Year
- SAVA N/A
- ATRA N/A
- Revenue Next Year
- SAVA N/A
- ATRA N/A
- P/E Ratio
- SAVA N/A
- ATRA $25.58
- Revenue Growth
- SAVA N/A
- ATRA 202.41
- 52 Week Low
- SAVA $1.15
- ATRA $5.01
- 52 Week High
- SAVA $33.98
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- SAVA 72.05
- ATRA 68.37
- Support Level
- SAVA $2.85
- ATRA $13.12
- Resistance Level
- SAVA $3.66
- ATRA $14.78
- Average True Range (ATR)
- SAVA 0.34
- ATRA 0.84
- MACD
- SAVA 0.10
- ATRA 0.16
- Stochastic Oscillator
- SAVA 92.90
- ATRA 86.14
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).